[ad_1]
A spin-off of Bellvitge Biomedical Research Institute (IDIBELL) from L’Hospitalet de Llobregat (Barcelona) has developed “The first blood biomarker” Able to anticipate the progression of mild cognitive deterioration towards Alzheimer’s dementia.
The company, Admit therapeuticshas had the Bellvitge Hospital as a clinical coordinating center, and the results have been published in the magazine isciencereports Bellvitge in a statement.
Unlike other recently developed blood biomarkers, which serve to confirm the presence of brain pathology, THE NEW TEST (MAP-AD) is prognosis and contributes “Decisive Clinical Information” about the future evolution of each patient.
The test has obtained the CE-IVDR marking, which certifies that meets the security and efficacy requirements of the European Union and open the door to its clinical application.
Research has included samples Patients with mild cognitive impairment and voluntary people without cognitive affectationcoming from several Catalan hospitals and the San Sebastián Cepe-Alzheimer’s Foundation, as well as the Biobancos of the University of Washington (United States) and the Australian Imaging, Biomarker and Lifestyle Study.
The test It consists of a qualitative blood analysis that measures new mitochondrial biomarks and combines them with clinical data to predict “with high precision” which patients with mild cognitive impairment will progress towards Alzheimer’s and which will remain stable.
A “reliable” tool
The study coordinator and head of the Memory Unit of the Neurology Service of the Bellvitge Hospital, Jordi Gascónhe explained that for years the underlying pathology could be identified, but it was “Very difficult” predict clinical evolution.
“Having a reliable tool that anticipates progression is a turning point: it allows us to hold more informed conversations with families and better guide interventionswhether preventive, in clinical trials or with new emerging therapies, “he concludes.
[ad_2]
Source link
